Kymera Therapeutics, Inc. (KYMR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KYMR SEC filings page.
Kymera Therapeutics, Inc. (KYMR) reported $105.0M in revenue over the twelve months to Jun 30, 2026, up 134.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Kymera is a development-stage business whose expanding research spend is financed by capital raises rather than operating cash generation.
The reported positive net income does not represent cash earnings: FY2025 shows net income of$311M alongside operating cash flow of-$233M and an operating loss of$349M . That gap, also present in FY2024, means non-operating accounting items are driving reported earnings while the core business continues consuming cash.
Research and development reached
The balance sheet expanded sharply as financing cash flow reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Kymera Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Kymera Therapeutics, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 15/100.
Kymera Therapeutics, Inc.'s revenue declined 16.7% year-over-year, from $47.1M to $39.2M. This contraction results in a growth score of 2/100.
Kymera Therapeutics, Inc. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 10.47, Kymera Therapeutics, Inc. holds $10.47 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 98/100.
Kymera Therapeutics, Inc.'s reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 1/100.
Kymera Therapeutics, Inc.'s ROE of 19.7% shows moderate profitability relative to equity, earning a score of 31/100. This is down from 26.8% the prior year.
Kymera Therapeutics, Inc. scores 33.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($9.3B) relative to total liabilities ($163.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Kymera Therapeutics, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Kymera Therapeutics, Inc. used $0.75 of operating cash (-$232.9M OCF vs $311.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Kymera Therapeutics, Inc. generated $65.0M in revenue in Q2 2026. This represents an increase of 466.4% from the same quarter a year earlier. Against the prior quarter it is up 89.1%.
Kymera Therapeutics, Inc.'s EBITDA was -$73.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.8% from the same quarter a year earlier. Against the prior quarter it is up 10.4%.
Kymera Therapeutics, Inc. reported -$61.2M in net income in Q2 2026. This represents an increase of 20.1% from the same quarter a year earlier. Against the prior quarter it is up 11.6%.
Kymera Therapeutics, Inc. earned -$0.62 per diluted share (EPS) in Q2 2026. This represents an increase of 34.7% from the same quarter a year earlier. Against the prior quarter it is up 12.7%.
Cash & Balance Sheet
Kymera Therapeutics, Inc. recorded an outflow of $54.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 10.0% from the same quarter a year earlier. Against the prior quarter it is up 38.9%.
Kymera Therapeutics, Inc. held $124.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Kymera Therapeutics, Inc.'s gross margin was 0.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.
Kymera Therapeutics, Inc.'s net profit margin was -94.2% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Kymera Therapeutics, Inc.'s ROE was -4.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.4 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Kymera Therapeutics, Inc. invested $119.5M in research and development in Q2 2026. This represents an increase of 52.4% from the same quarter a year earlier. Against the prior quarter it is up 21.7%.
Kymera Therapeutics, Inc. invested $473K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 31.9% from the same quarter a year earlier. Against the prior quarter it is up 9.0%.
Not reported for Q2 2026.
KYMR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.0M+466.4% | $34.4M+55.5% | $2.9M-61.2% | $2.8M-26.1% | $11.5M-55.3% | $22.1M+114.8% | $7.4M-84.6% | $3.7M-20.9% |
| Cost of Revenue | $65.0M+466.4% | $34.4M+55.5% | $2.9M-61.2% | $2.8M-26.1% | $11.5M-55.3% | $22.1M+114.8% | $7.4M | $3.7M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D Expenses | $119.5M+52.4% | $98.2M+22.3% | $83.8M+16.7% | $74.1M+22.7% | $78.4M+32.4% | $80.3M+64.4% | $71.8M+35.6% | $60.4M+25.5% |
| SG&A Expenses | $21.1M+19.7% | $20.4M+25.1% | $16.9M+3.7% | $17.3M+12.2% | $17.6M+1.6% | $16.3M+13.2% | $16.3M+14.8% | $15.5M+9.5% |
| Operating Income | -$75.6M+10.6% | -$84.2M-13.1% | -$97.9M-21.2% | -$92.5M-28.3% | -$84.6M-66.0% | -$74.4M-28.7% | -$80.8M-318.2% | -$72.1M-25.4% |
| EBITDA | -$73.6M+10.8% | -$82.1M-13.5% | -$96.2M-21.2% | -$90.0M-28.9% | -$82.5M-69.6% | -$72.4M-28.4% | -$79.4M-314.5% | -$69.8M-24.1% |
| Net Income | -$61.2M+20.1% | -$69.2M-5.6% | $535.7M+42.1% | -$82.2M-31.5% | -$76.6M-82.1% | -$65.6M-35.1% | $377.0M+34.8% | -$62.5M-18.2% |
| EPS (Basic) | -$0.62+34.7% | -$0.71+13.4% | -$0.98-10.1% | -$0.94-14.6% | -$0.95-63.8% | -$0.82-18.8% | -$0.89-256.0% | -$0.82+8.9% |
| EPS (Diluted) | -$0.62+34.7% | -$0.71+13.4% | -$0.98-10.1% | -$0.94-14.6% | -$0.95-63.8% | -$0.82-18.8% | -$0.89-256.0% | -$0.82+8.9% |
| Diluted Shares (Avg) | 98M+22.0% | 98M+21.7% | N/A | 87M+14.7% | 80M+10.1% | 80M+13.2% | N/A | 76M+30.3% |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
KYMR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B+45.5% | $1.7B+81.7% | $1.7B+78.2% | $1.1B+6.5% | $1.1B+36.9% | $918.3M+5.8% | $978.0M+69.9% | $1.0B+87.3% |
| Current Assets | $737.3M+1.2% | $677.4M+35.2% | $871.2M+70.7% | $528.3M-7.1% | $728.3M+38.6% | $501.0M-6.8% | $510.3M+25.9% | $568.7M+51.4% |
| Cash & Equivalents | $124.5M-62.9% | $144.1M+60.2% | $357.0M+196.9% | $112.9M+2.0% | $335.8M+396.7% | $90.0M-3.8% | $120.3M+9.4% | $110.7M+36.6% |
| Short-Term Investments | $566.5M+71.9% | $506.8M+35.8% | $491.3M+33.3% | $392.7M-10.6% | $329.6M-25.5% | $373.2M-12.6% | $368.5M+39.1% | $439.3M+58.7% |
| Accounts Receivable | $20.0M-50.0% | N/A | $0 | N/A | $40.0M | N/A | $0-100.0% | $0 |
| Long-Term Investments | $813.9M+173.5% | $894.7M+186.5% | $771.2M+112.9% | $473.1M+31.0% | $297.6M+54.7% | $312.3M+39.2% | $362.2M+489.5% | $361.0M+368.9% |
| Total Liabilities | $136.2M-14.7% | $129.4M-2.0% | $163.1M+14.6% | $155.8M+9.8% | $159.6M+13.1% | $132.1M-15.9% | $142.4M-21.2% | $141.9M-9.5% |
| Current Liabilities | $71.3M-18.5% | $62.6M+6.2% | $83.2M+22.8% | $71.6M+7.6% | $87.5M+40.9% | $59.0M+5.1% | $67.8M-20.9% | $66.5M+5.3% |
| Non-Current Liabilities | $64.9M-10.0% | $66.7M-8.7% | $79.9M+7.1% | $84.2M+11.7% | $72.0M-8.7% | $73.1M-27.6% | $74.6M-21.5% | $75.4M-19.5% |
| Total Equity | $1.5B+55.4% | $1.5B+95.8% | $1.6B+89.0% | $946.3M+6.0% | $971.5M+41.8% | $786.2M+10.5% | $835.6M+111.6% | $892.9M+125.8% |
| Retained Earnings | -$1.2B-33.4% | -$1.1B-38.4% | -$1.1B-41.3% | -$979.0M-43.2% | -$896.8M-44.3% | -$820.2M-41.6% | -$754.6M-42.2% | -$683.9M-32.4% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
KYMR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$54.1M+9.7% | -$88.8M-12.2% | -$66.7M-8.0% | -$27.1M+46.0% | -$59.9M-39.5% | -$79.2M-99.9% | -$61.8M-868.0% | -$50.2M-58.6% |
| Depreciation & Amortization | $2.0M-2.2% | $2.0M-1.3% | $2.0M+2.3% | $2.5M+9.8% | $2.1M-9.0% | $2.0M+40.2% | $2.0M+123.0% | $2.3M+82.3% |
| Stock-Based Compensation | $18.9M+22.9% | $16.0M+12.5% | N/A | $15.8M+6.0% | $15.4M+7.5% | $14.2M+18.9% | N/A | $14.9M+27.9% |
| Capital Expenditures | $473K-31.9% | $434K-7.1% | $106K-88.7% | $181K-4.2% | $695K-85.2% | $467K-93.7% | $936K-91.9% | -$189K-97.7% |
| Free Cash Flow | -$54.5M+10.0% | -$89.3M-12.1% | -$66.9M-6.6% | -$27.3M+45.8% | -$60.6M-27.2% | -$79.6M-69.4% | -$62.7M-1652.0% | -$50.4M-26.8% |
| Investing Cash Flow | $20.0M-66.6% | -$142.8M-393.8% | -$394.4M-675.2% | -$235.3M-49.2% | $60.0M+283.7% | $48.6M+114.7% | $68.6M+261.8% | -$157.7M-360.6% |
| Financing Cash Flow | $14.4M-94.1% | $18.8M+7174.8% | $705.2M+25405.2% | $39.5M-84.3% | $245.7M+17302.7% | $258K-99.9% | $2.8M+43.0% | $250.9M+121904.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
KYMR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0% | 0.0% |
| Operating Margin | -116.3% | -244.9% | -3409.8% | -3347.4% | -736.8% | -336.8% | -1092.2% | -1927.9% |
| Net Margin | -94.2% | -201.5% | 18659.7% | -2973.0% | -667.6% | -296.8% | 5098.2% | -1670.3% |
| Return on Equity | -4.1%+3.8pp | -4.5%+3.8pp | 33.9%-11.2pp | -8.7%-1.7pp | -7.9%-1.7pp | -8.3%-1.5pp | 45.1%-25.7pp | -7.0%+6.4pp |
| Return on Assets | -3.7%+3.0pp | -4.2%+3.0pp | 30.7%-7.8pp | -7.5%-1.4pp | -6.8%-1.7pp | -7.1%-1.6pp | 38.5%-10.0pp | -6.0%+3.5pp |
| Current Ratio | 10.34+2.0x | 10.81+2.3x | 10.47+2.9x | 7.38-1.2x | 8.32-0.1x | 8.49-1.1x | 7.53+2.8x | 8.55+2.6x |
| Debt-to-Equity | 0.09-0.1x | 0.08-0.1x | 0.10-0.1x | 0.160.0x | 0.160.0x | 0.17-0.1x | 0.17-0.3x | 0.16-0.2x |
| Asset Turnover | 0.040.0x | 0.020.0x | 0.000.0x | 0.000.0x | 0.010.0x | 0.020.0x | 0.01-0.1x | 0.000.0x |
| FCF Margin | -83.9% | -259.8% | -2328.6% | -987.4% | -527.9% | -360.3% | -848.3% | -1346.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. KYMR | FY2025 | $39.2M | $311.4M | N/A | $9.3B | 38/100 |
| MoonLake Immunotherapeutics MLTX | FY2025 | N/A | -$227.3M | N/A | $920.9M | — |
| Apellis Pharmaceuticals, Inc. APLS | FY2025 | $1.0B | $22.4M | 2.2% | $5.3B | 42/100 |
| Crinetics Pharmaceuticals, Inc. CRNX | FY2025 | $7.7M | -$465.3M | N/A | $9.0B | 60/100 |
| Scholar Rock Holding Corporation SRRK | FY2025 | $0 | -$378.0M | N/A | $5.1B | — |
| Zai Lab Limited ZLAB | FY2025 | $460.2M | -$175.5M | -38.1% | $2.8B | 65/100 |
Where Kymera Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Kymera Therapeutics, Inc.'s annual revenue?
Kymera Therapeutics, Inc. (KYMR) reported $39.2M in total revenue for fiscal year 2025. This represents a -16.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Kymera Therapeutics, Inc.'s revenue growing?
Kymera Therapeutics, Inc. (KYMR) revenue declined by 16.7% year-over-year, from $47.1M to $39.2M in fiscal year 2025.
Is Kymera Therapeutics, Inc. profitable?
Yes, Kymera Therapeutics, Inc. (KYMR) reported a net income of $311.4M in fiscal year 2025.
What is Kymera Therapeutics, Inc.'s EBITDA?
Kymera Therapeutics, Inc. (KYMR) had EBITDA of -$341.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Kymera Therapeutics, Inc.'s gross margin?
Kymera Therapeutics, Inc. (KYMR) had a gross margin of 0.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Kymera Therapeutics, Inc.'s return on equity (ROE)?
Kymera Therapeutics, Inc. (KYMR) has a return on equity of 19.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Kymera Therapeutics, Inc.'s free cash flow?
Kymera Therapeutics, Inc. (KYMR) recorded an outflow of $234.3M in free cash flow during fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Kymera Therapeutics, Inc.'s operating cash flow?
Kymera Therapeutics, Inc. (KYMR) recorded an outflow of $232.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Kymera Therapeutics, Inc.'s total assets?
Kymera Therapeutics, Inc. (KYMR) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Kymera Therapeutics, Inc.'s capital expenditures?
Kymera Therapeutics, Inc. (KYMR) invested $1.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Kymera Therapeutics, Inc. spend on research and development?
Kymera Therapeutics, Inc. (KYMR) invested $316.6M in research and development during fiscal year 2025.
What is Kymera Therapeutics, Inc.'s current ratio?
Kymera Therapeutics, Inc. (KYMR) had a current ratio of 10.47 as of fiscal year 2025, which is generally considered healthy.
What is Kymera Therapeutics, Inc.'s debt-to-equity ratio?
Kymera Therapeutics, Inc. (KYMR) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Kymera Therapeutics, Inc.'s return on assets (ROA)?
Kymera Therapeutics, Inc. (KYMR) had a return on assets of 17.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Kymera Therapeutics, Inc.'s P/E ratio?
Kymera Therapeutics, Inc. (KYMR) trades at 28.9x earnings, its market capitalization divided by net income of $323.1M net income, trailing 12 months to June 30, 2026. The market capitalization is $9.3B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Kymera Therapeutics, Inc.'s price-to-sales ratio?
Kymera Therapeutics, Inc. (KYMR) trades at 89.0x sales, its market capitalization divided by revenue of $105.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $9.3B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Kymera Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Kymera Therapeutics, Inc. (KYMR) held $1.6B in cash, cash equivalents and investments, and reported an operating cash outflow of $232.9M over that year. Dividing the one by the other, the reported balance equals about 83 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Kymera Therapeutics, Inc.'s Altman Z-Score?
Kymera Therapeutics, Inc. (KYMR) has an Altman Z-Score of 33.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kymera Therapeutics, Inc.'s Piotroski F-Score?
Kymera Therapeutics, Inc. (KYMR) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kymera Therapeutics, Inc.'s earnings high quality?
For every $1 of reported earnings, Kymera Therapeutics, Inc. (KYMR) used $0.75 of operating cash (-$232.9M OCF vs $311.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Kymera Therapeutics, Inc.?
Kymera Therapeutics, Inc. (KYMR) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.